1995 Results

People

  1. Kris
    Kris
  2. Motzer
    Motzer
  3. Scher
    Scher
  4. Saltz
    Saltz
  5. Schwartz
    Schwartz
  6. Hudis
    Hudis
  7. Kelsen
    Kelsen
  8. Rosen
    Rosen
  9. Marks
    Marks
  10. De Angelis
    De Angelis

Groups

  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)
  7. Sloan Kettering Institute Faculty (227)
  8. Hematologic Malignancies, Division of (224)
  9. Genitourinary Oncology Service (203)
  10. Molecular Pharmacology and Chemistry Program Faculty (172)
  1. "antineoplastic agents"
Formats
  1. Journal Article (1901)
  2. Review (47)
  3. Conference Paper (23)
  4. Editorial (7)
  5. Research Letter (6)
  6. Guidelines (4)
  7. Book Section (3)
  8. Correspondence (2)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)

More Groups

People
  1. Mark Kris (77)
  2. Robert Motzer (70)
  3. Howard Scher (58)
  4. Gary Schwartz (52)
  5. Leonard Saltz (52)
  6. Ting-Chao Chou (50)

More People

Years
  1. 2025 (16)
  2. 2024 (65)
  3. 2023 (49)
  4. 2022 (49)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Clinical Cancer Research (114)
  2. Journal of Clinical Oncology (111)
  3. Cancer (70)
  4. Seminars in Oncology (51)
  5. New England Journal of Medicine (43)
  6. Cancer Research (40)

More Publications

Publishers
  1. Elsevier Inc. (240)
  2. American Association for Cancer Research (187)
  3. Springer (175)
  4. American Society of Clinical Oncology (129)
  5. Wiley Blackwell (112)
  6. Nature Publishing Group (92)

More Publishers

Results (1995)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells
    Journal Article

    Yankelevich, M.; Thakur, A.; Modak, S.; Chu, R.; Taub, J.; Martin, A.; Schalk, D.; Schienshang, A.; Whitaker, S.; Rea, K.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Pharmacy assistance programs for oral anticancer drugs: A narrative review
    Review

    Ragavan, M. V.; Swartz, S.; Clark, M.; Chino, F.
    JCO Oncology Practice (2024)

    Fulltext@MSK | Save
  • A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer
    Journal Article

    Dorff, T.; Horvath, L. G.; Autio, K.; Bernard-Tessier, A.; Rettig, M. B.; Machiels, J. P.; Bilen, M. A.; Lolkema, M. P.; Adra, N.; Rottey, S.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Management of patients with advanced-stage HER2-positive breast cancer: Current evidence and future perspectives
    Review

    Marra, A.; Chandarlapaty, S.; Modi, S.
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies
    Journal Article

    Stein, E. M.; Fathi, A. T.; Harb, W. A.; Colak, G.; Fusco, A.; Mangan, J. K.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Journal Article

    Jabbour, E.; Apperley, J.; Cortes, J.; Rea, D.; Deininger, M.; Abruzzese, E.; Chuah, C.; DeAngelo, D. J.; Hochhaus, A.; Lipton, J. H.; more...
    Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of pain and adverse health outcomes on long-term US testicular cancer survivors
    Journal Article

    Dinh, P. C. Jr; Monahan, P. O.; Fosså, S. D.; Sesso, H. D.; Feldman, D. R.; Dolan, M. E.; Nevel, K.; Kincaid, J.; Vaughn, D. J.; Martin, N. E.; more...
    JNCI: Journal of the National Cancer Institute (2024)

    Fulltext@MSK | Save
  • TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer
    Journal Article

    Bardia, A.; Jhaveri, K.; Kalinsky, K.; Pernas, S.; Tsurutani, J.; Xu, B.; Hamilton, E.; Im, S. A.; Nowecki, Z.; Sohn, J.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Next-generation therapies for pancreatic cancer
    Review

    Buckley, C. W.; O’Reilly, E. M.
    Expert Review of Gastroenterology and Hepatology (2024)

    Fulltext@MSK | Save
  • Antibody–drug conjugates and ocular toxicity: Nursing, patient, and organizational implications for care
    Review

    Clark, C.; Komo, I.
    Clinical Journal of Oncology Nursing (2024)

    Fulltext@MSK | Save